Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54 - Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p

#BBIO Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

www.stocktitan.net/news/BBIO/acoramidis-sig...

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on March 30, 2026.The NDA includes interim Phase 3 FORTIFY data showing statistically significant, clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio anticipates U.S. approval and a launch in late 2026/early 2027, is seeking expedited paths in Europe, and notes prior Orphan Drug, Fast Track, and Rare Pediatric designations.

#BBIO BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

www.stocktitan.net/news/BBIO/bridge-bio-sub...

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 BridgeBio (Nasdaq: BBIO) presented positive Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showing rapid, consistent efficacy and a favorable safety profile.Key results: 31-second 100MTT benefit at 12 months, CK reductions with 38.3% normalization, comparable serious adverse event rates, and an intended NDA submission in H1 2026.

#BBIO BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

www.stocktitan.net/news/BBIO/bbp-418-demons...

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,”

#BBIO BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

www.stocktitan.net/news/BBIO/bridge-bio-pri...

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference - Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632

#BBIO BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/BBIO/bridge-bio-ann...

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study 69% risk reduction in ACM/

#BBIO Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

www.stocktitan.net/news/BBIO/acoramidis-sig...

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates - $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique

#BBIO BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/BBIO/bridge-bio-rep...

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study BridgeBio (Nasdaq: BBIO) reported positive topline Phase 3 FORTIFY results for oral small molecule BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on Oct 27, 2025. Key clinical and biomarker readouts at the planned 12-month interim analysis met endpoints with a favorable safety profile.Highlights include a 1.8x increase in glycosylated αDG (~17% of control, p<0.0001) sustained to 12 months, an 82% reduction in serum CK (p<0.0001), ambulatory improvement of +0.14 m/s from baseline and +0.27 m/s vs placebo (p<0.0001), and pulmonary benefit of ~+3% predicted FVC from baseline and ~+5% vs placebo (p=0.0071). The company intends to file an NDA with the FDA in H1 2026.

#BBIO BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

www.stocktitan.net/news/BBIO/bridge-bio-rep...

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM BridgeBio Pharma (Nasdaq: BBIO) presented groundbreaking data from the ATTRibute-CM study showing that acoramidis, their oral TTR stabilizer, demonstrates rapid efficacy in treating ATTR-CM (transthyretin amyloid cardiomyopathy). The drug showed significant cardiovascular benefits within the first month of treatment.Key findings include a 49% hazard reduction in cardiovascular mortality or recurrent hospitalizations through Month 30 (p53 events avoided per 100 treated participants. At Month 42, continuous acoramidis treatment reduced cardiovascular mortality by 45% compared to placebo-to-acoramidis switch (p=0.0011).Acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, Japan, and the UK, has received regulatory approval with labels specifying near-complete TTR stabilization.

#BBIO Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

www.stocktitan.net/news/BBIO/acoramidis-beg...

80% Success Rate: BridgeBio's Encaleret Normalizes Calcium Levels in Breakthrough Hypoparathyroidism Study Phase 2 trial shows encaleret normalized blood and urine calcium in 80% of post-surgical hypoparathyroidism patients within 5 days. Registrational study planned for 2026.

#BBIO Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

www.stocktitan.net/news/BBIO/encaleret-show...

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension BridgeBio Pharma (Nasdaq: BBIO) announced significant results from the ATTRibute-CM open label extension study of acoramidis through Month 42. The drug demonstrated a 44% reduction in cardiovascular mortality risk for patients with ATTR-CM. Additional key findings include a 46% hazard reduction in the composite outcome of cardiovascular mortality or first cardiovascular hospitalization.The study showed that acoramidis, marketed as Attruby® in the US and BEYONTTRA® in Europe, achieved disease stabilization in about 50% of participants compared to less than 20% with placebo at Month 30, as measured by NT-proBNP levels. The drug demonstrated the fastest benefit observed in any Phase 3 ATTR-CM study to date, with results visible in just 3 months.The data was presented at the European Society of Cardiology Congress 2025 in Madrid, highlighting acoramidis's potential as a transformative therapy for ATTR-CM patients.

#BBIO Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

www.stocktitan.net/news/BBIO/acoramidis-dem...

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates BridgeBio Pharma (Nasdaq: BBIO) reported strong Q2 2025 financial results, with total revenue of $110.6 million, including $71.5 million from Attruby® net product revenue. The company's flagship drug Attruby has gained significant traction with 3,751 unique patient prescriptions from 1,074 unique prescribers.New analyses from the ATTRibute-CM study reinforced Attruby's clinical profile, showing a 59% relative risk reduction in variant ATTR-CM patients and a 31.6% relative risk reduction in mortality associated with increased TTR stabilization. The company ended Q2 with a strong cash position of $756.9 million.BridgeBio expects multiple key Phase 3 trial results in fall 2025, including FORTIFY (BBP-418 for LGMD2I/R9) and CALIBRATE (encaleret for ADH1), with PROPEL 3 (infigratinib for achondroplasia) results expected in early 2026.

#BBIO BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/BBIO/bridge-bio-rep...

BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty BridgeBio Pharma (Nasdaq: BBIO) has secured a $300 million upfront payment through a partial monetization of European royalties for BEYONTTRA®, their ATTR-CM treatment. The deal involves selling 60% of royalties on the first $500 million of annual BEYONTTRA European sales to HealthCare Royalty and Blue Owl Capital, with payments capped at 1.45x.The transaction builds upon BridgeBio's existing partnership with Bayer Consumer Care AG, from which they've already received $210 million in upfront and regulatory milestones, with an additional $75 million in near-term milestone payments expected. The Bayer agreement includes tiered royalties starting in the low-30% range on European net sales.Clinical data from the ATTRibute-CM study showed significant efficacy, including a 42% reduction in composite ACM and recurrent CVH events at Month 30, and a 50% reduction in cumulative CVH events. The drug is now approved as Attruby in the U.S. and as BEYONTTRA in Europe, Japan, and the UK. [ "Secured $300 million immediate non-dilutive capital through royalty monetization", "Already received $210 million in upfront and regulatory milestones from Bayer partnership", "Additional $75 million in near-term milestone payments expected", "Clinical trials showed 42% reduction in composite ACM and CVH events", "Achieved 50% reduction in cumulative CVH events in Phase 3 study", "Obtained regulatory approvals across major markets (US, Europe, Japan, UK)", "Structured deal preserves upside potential with 1.45x payment cap" ]

#BBIO BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty

www.stocktitan.net/news/BBIO/bridge-bio-rai...

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM BridgeBio Pharma (NASDAQ: BBIO) presented promising data from the ATTRibute-CM study for acoramidis (marketed as Attruby/BEYONTTRA) in treating ATTR-CM. The drug showed a 43% reduction in cardiovascular hospitalizations due to atrial fibrillation and a 17% reduction in new-onset AF in patients without prior history. Key findings include: - 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations at Month 30 - 50% reduction in cumulative frequency of cardiovascular hospitalization events - 86.7-meter improvement in 6-minute walk distance for variant ATTR-CM patients - 20.3-point improvement in quality of life scores The drug is already approved by FDA, European Commission, Japanese PMDA, and UK MHRA. Results suggest acoramidis could be considered as a first-line treatment for ATTR-CM patients, particularly beneficial for those with the hereditary variant form (ATTRv-CM).

#BBIO Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

www.stocktitan.net/news/BBIO/acoramidis-red...

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study BridgeBio Pharma (NASDAQ: BBIO) published significant findings from its ATTRibute-CM Phase 3 trial of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The study revealed that for every 5-mg/dL increase in serum TTR levels within 28 days of treatment, mortality risk reduced by up to 31.6% through Month 30. The drug demonstrated rapid benefits, including a 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalizations at Month 30, and a 50% reduction in cardiovascular hospitalization events. Treatment resulted in an early rise in serum TTR levels (mean 9.1 mg/dL) within 28 days, sustained throughout the 30-month period. Acoramidis is now approved as Attruby in the US and as BEYONTTRA in Europe, Japan, and the UK.

#BBIO Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

www.stocktitan.net/news/BBIO/early-and-sust...

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study BridgeBio Pharma (NASDAQ: BBIO) has initiated ACT-EARLY, the first-ever primary prevention study for ATTR amyloidosis, with the first participant receiving acoramidis. The study will enroll ~600 asymptomatic carriers of pathogenic TTR variants to evaluate if early intervention can prevent or delay disease onset. This follows significant results from the ATTRibute-CM Phase 3 trial, where acoramidis showed a 59.1% risk reduction in ATTRv-CM patients. The drug, approved as Attruby™ in the US and BEYONTTRA® in Europe, Japan, and the UK, is a near-complete TTR stabilizer. The primary endpoint will measure time to development of ATTR-CM and/or ATTR-PN, addressing a critical unmet need for at-risk individuals who currently have no preventative treatment options.

#BBIO First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

www.stocktitan.net/news/BBIO/first-particip...

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates BridgeBio Pharma reported strong Q1 2025 results, with $36.7 million in first-quarter U.S. Attruby net product revenue. The company has seen 2,072 unique patient prescriptions from 756 healthcare providers since FDA approval in November 2024. Key highlights: Cash position of $540.6 million, with additional $105 million in milestone payments expected in Q2 Total revenues of $116.6 million for Q1 2025 Successful global expansion with BEYONTTRA approvals in EU, UK, and Japan Positive results in hypochondroplasia and hypoparathyroidism trials The company's pipeline shows progress across multiple programs, including acoramidis for ATTR-CM, BBP-418 for LGMD2I/R9, and encaleret for ADH1. Notable achievements include a 42% reduction in all-cause mortality for Attruby and 78% success rate in encaleret's proof-of-principle study for hypoparathyroidism.

#BBIO BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

www.stocktitan.net/news/BBIO/bridge-bio-rep...

🚨 #Earnings Trades We're Entering Tonight:

#TW
#NOG
#AER
#CSGP
#GNRC
#BXMT
#YUM
#ASTL
#AMCR
#PPL
#CWH
#GTES
#EQNR
#IP
#HES
#UBS
#BBIO
#OKE
#SMG
#GSK
#GEHC
#ETSY
#STLA
#CZR
#WDC
#NCLH
#FSLR
#SBUX

Where else do you get trades before they happen?

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM BridgeBio Pharma (BBIO) has received UK approval for BEYONTTRA® (acoramidis), the first near-complete TTR stabilizer (≥90%) for treating ATTR-CM (transthyretin amyloidosis with cardiomyopathy). The approval is based on the Phase 3 ATTRibute-CM study results, which demonstrated:42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 3050% reduction in cumulative frequency of cardiovascular hospitalization eventsRapid benefit showing separation from placebo in as few as 3 monthsBEYONTTRA is now approved in the US, EU, UK, and Japan. Under a collaboration agreement with Bayer, who will handle UK commercialization, BridgeBio will receive tiered royalties starting in the low-thirties percent on sales.

#BBIO BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

www.stocktitan.net/news/BBIO/beyonttra-acor...

Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment Novel PanKRAS inhibitor shows exceptional potency in targeting both ON/OFF states. First-in-class molecule advances BBOT's cancer pipeline. Full analysis inside.

#BBIO BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

www.stocktitan.net/news/BBIO/bbot-announces...

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM BridgeBio Pharma (BBIO) announced significant clinical outcomes for acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The drug showed a 59% risk reduction in variant ATTR-CM patients and 31.2% reduction in wild-type ATTR-CM patients for the composite of all-cause mortality (ACM) and cardiovascular-related hospitalization (CVH).Key highlights from the ATTRibute-CM Phase 3 trial include:Hazard ratio of 0.41 for ATTRv-CM patients42% reduction in composite ACM and recurrent CVH events at Month 3050% reduction in cumulative CVH events at Month 30Benefits observed in as few as 3 monthsAcoramidis, approved as Attruby™ in the US and BEYONTTRA™ in Europe and Japan, demonstrates near-complete (≥90%) TTR stabilization. The drug showed improved outcomes in both variant and wild-type ATTR-CM patients, with statistically significant results in both subgroups.

#BBIO Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

www.stocktitan.net/news/BBIO/acoramidis-sho...

Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan First-in-class TTR stabilizer shows unprecedented 42% mortality reduction in ATTR-CM patients. $30M milestone payment secured. Launch set for 2025. Full analysis inside.

#BBIO Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

www.stocktitan.net/news/BBIO/beyonttra-tm-a...

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt BridgeBio Pharma (BBIO) has priced a $500 million convertible senior notes offering due 2031, with an additional $75 million option for initial purchasers. The notes, priced at a 1.75% interest rate with a 45% conversion premium, will be convertible into cash, company shares, or a combination thereof.The company expects net proceeds of approximately $489.5 million (or $563.0 million if the additional option is exercised). These funds will be used to repay outstanding borrowings under its Financing Agreement with Blue Owl , which accounted for $51.5 million in interest payments in 2024. Additionally, $48.3 million will be used to repurchase 1,405,411 shares at $34.35 per share.The notes will mature on March 1, 2031, with an initial conversion rate of 20.0773 shares per $1,000 principal amount, equivalent to a conversion price of $49.81 per share.

#BBIO BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

www.stocktitan.net/news/BBIO/bridge-bio-pri...

Can BridgeBio's $500M Debt Makeover Transform Its Financial Future? Strategic refinancing aims to reduce interest burden and extend debt maturity to 2031, while funding $50M share buyback and eliminating restrictive covenants.

#BBIO BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

www.stocktitan.net/news/BBIO/bridge-bio-ini...

Can BridgeBio's Blockbuster Drug Launch Transform Its Financial Future? Key Metrics Revealed Attruby launch momentum with 1,028 prescriptions, EU approval secured. Revenue surges to $221.9M with $681.2M cash position. Multiple catalysts ahead in 2025.

#BBIO BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

www.stocktitan.net/news/BBIO/bridge-bio-pha...

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #QUBT 9.7x
2. #MVIS 9.1x
3. #BBIO 8.5x
4. #AR 7.8x
5. #AON 7.2x

#OptionFlow #OptionsTrading #Trading

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM BridgeBio Pharma (BBIO) has received European Commission approval for BEYONTTRA™ (acoramidis), the first near-complete TTR stabilizer (≥90%) to treat ATTR-CM, a fatal heart condition. The approval is based on the Phase 3 ATTRibute-CM study results, which showed:- 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30- 50% reduction in cumulative frequency of cardiovascular-related hospitalization events at Month 30- Benefits observed in as few as 3 monthsFollowing the approval, BridgeBio will receive a $75 million milestone payment from Bayer, who will handle EU commercialization. BridgeBio will also receive tiered royalties starting in the low-thirties percent on EU sales. Bayer plans to launch the drug in the first half of 2025. The drug was previously approved in the U.S. as Attruby™ in November 2024, with 430 patient prescriptions written by 248 physicians since approval.

#BBIO BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

www.stocktitan.net/news/BBIO/beyonttratm-ac...

ORTEX - Global Financial Analytics ORTEX - Global Financial Analytics with live short interest, options, analyst data and much more

🚀 #BBIO
Bullish Put/Call Ratio at 0.2. Normal range: 0.32 - 0.58.
Short Interest up +5.43% to 15.93% of float over the past 7 days.

Get 50% off an advanced subscription and access valuable market insights. Don't miss out on this offer!

Sign up here:
app.ortex.com?promo=2025&p...

ORTEX - Global Financial Analytics ORTEX - Global Financial Analytics with live short interest, options, analyst data and much more

🚀 #BBIO
Very Bullish Put/Call Ratio at 0.16 — Normal Range: 0.34–0.59.
Short Interest up 0.47% in 7 days, now at 15.08 % of float.

Don’t miss this week’s promo — $9 gets you a full month of insights like this!
app.ortex.com?promo=2025&p...

#BBIO #ShortInterest #Options #Trading #Investing #ORTEX